Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
RSV fusion protein inhibitor
Enzaplatovir is an inhibitor of Respiratory Syncytial Virus (RSV). It can be used as a viral fusion protein inhibitor. -
RSV fusion inhibitor
Syncytial Virus Inhibitor-1 is a potent, orally bioavailable respiratory syncytial virus (RSV) fusion inhibitor with EC50s of 0.002 μM, 0.004 μM, and 0.002 μM for RSV Long, RSV A2, and RSV B strains, respectively. -
RSV polymerase inhibitor
Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase. -
RSV replication inhibitor
RSV604 R enantiomer is the R-enantiomer of RSV604. RSV604 is an inhibitor of respiratory syncytial virus (RSV) replication. R-enantiomer is less active against RSV. -
RSV Polymerase Inhibitor
JNJ-8003 is a highly potent, orally active non-nucleoside inhibitor of respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 of 0.29 nM. It specifically targets the L protein of the polymerase complex, effectively blocking the transcription and replication of the viral genome by inhibiting RNA-dependent RNA polymerase (RdRp) activity, with an IC50 of 0.67 nM. In vitro studies demonstrate subnanomolar efficacy, and it has shown significant effectiveness in mouse and neonatal lamb models. JNJ-8003 is a valuable reagent for investigating RSV biology and developing antiviral therapies. -
RSV RdRp Inhibitor
GS-646089 is a potent inhibitor of respiratory syncytial virus (RSV) RNA-dependent RNA polymerase (RdRp). This broad-spectrum antiviral nucleoside analog demonstrates robust activity against RSV, human metapneumovirus (hMPV), rhinovirus, and enteroviruses, with an IC50 in the range of 43 to 46 nM. GS-646089 is converted intracellularly into a triphosphate metabolite that competes with ATP for incorporation into growing RNA chains, effectively terminating viral replication. This compound serves as a valuable tool for research into acute respiratory viral infections and related viral pathogens. -
RSV Inhibitor
CL-A3-7 is a potent respiratory syncytial virus (RSV) inhibitor that targets the RSV F protein, functioning as a virus-cell fusion inhibitor. By disrupting the interaction between the virus and the host insulin-like growth factor 1 receptor (IGF1R), CL-A3-7 effectively prevents infections caused by both wild-type RSV and the K394R variant. This compound is valuable for use in anti-RSV drug development and studies focused on resistance mechanisms associated with RSV. -
RSV fusion inhibitor
Sisunatovir, also known as RV521, is a highly potent fusion inhibitor with efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses. -
PRRSV Inhibitor
Atractylodinol is a potent inhibitor of the porcine reproductive and respiratory syndrome virus (PRRSV). It exerts its antiviral activity by binding to vimentin, leading to the inhibition of TGF-β receptor I recycling and the formation of filamentous aggregates. This compound is valuable for research focused on understanding PRRSV pathogenesis and developing therapeutic strategies against viral infections in swine. -
PRRSV/CD163 Inhibitor
PRRSV/CD163-IN-1 is a specific inhibitor of the interaction between porcine reproductive and respiratory syndrome virus (PRRSV) glycoproteins GP2a or GP4 and the CD163-SRCR5 domain. This compound is valuable for studying the mechanisms of PRRSV infection and the role of CD163 in viral entry. It is an essential tool for research aimed at understanding porcine reproductive and respiratory syndrome and developing potential therapeutic strategies. -
PRRSV Inhibitor
PRRSV-IN-1 is a non-structural protein 4 (nsp4) protease inhibitor specifically targeting Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). This compound demonstrates potent antiviral activity, exhibiting an EC50 of 0.45 μM and effectively inhibiting nsp4 protease activity with an IC50 of 80.36 pM. PRRSV-IN-1 is a valuable tool for investigating antiviral strategies and understanding PRRSV pathogenesis in research applications. -
RSV Inhibitor
RSV-IN-3 is a dual inhibitor targeting respiratory syncytial virus (RSV) and influenza virus A (IAV). It demonstrates significant anti-RSV activity with an EC50 value of 32.70 μM. RSV-IN-3 can be utilized in research focused on viral pathogenesis and the development of antiviral therapeutics for respiratory viral infections. -
RSV/IAV Inhibitor
RSV/IAV-IN-3 is a dual inhibitor targeting both respiratory syncytial virus (RSV) and influenza A virus (IAV) with reported EC50 values of 2.92 µM and 1.90 µM, respectively. This compound exhibits significant antiviral activity against H1N1 and H3N2 strains, achieving EC50 values of 3.25 µM and 1.50 µM in MDCK cells. Notably, RSV/IAV-IN-3 inhibits IAV infectivity and RNA-dependent RNA polymerase (RdRp) activity while effectively suppressing viral replication at the post-entry stage. Its influence on luciferase activity further emphasizes its potential in antiviral research applications. -
RSV Inhibitor
RSV-IN-4 is a dual inhibitor targeting respiratory syncytial virus (RSV) and influenza virus A (IAV). This compound demonstrates significant anti-RSV activity, achieving an EC50 of 11.76 μM. RSV-IN-4 is primarily utilized in research applications focused on antiviral drug development and understanding viral pathogenesis. -
RSV/IAV Inhibitor
RSV/IAV-IN-2 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) and influenza A virus (IAV). This compound demonstrates reduced cytotoxicity compared to the established antiviral Ribavirin, making it a valuable candidate for studies focused on RSV and/or IAV infections. Its efficacy in inhibiting viral replication supports its use in antiviral research and therapeutic development against these respiratory pathogens. -
RSV/IAV Inhibitor
RSV/IAV-IN-1 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) and influenza A virus (IAV). This compound exhibits reduced cytotoxicity compared to the clinical antiviral agent Ribavirin, making it a valuable tool for studying RSV and IAV infections. RSV/IAV-IN-1 facilitates research into antiviral mechanisms and therapeutic strategies against these viral pathogens. -
RSV Fusion Glycoprotein Inhibitor
CGR-50 is a selective inhibitor of the respiratory syncytial virus (RSV) fusion glycoprotein, demonstrating potent activity with an EC50 of 32.6 nM against RSV A2 in HEp-2 cell lines. This compound effectively blocks RSV entry by binding to the F protein, thereby inhibiting the critical process of membrane fusion. CGR-50 is a valuable tool for research dedicated to understanding and combating RSV infections. -
RSV-F Protein Inhibitor
Sisunatovir is a potent inhibitor of the respiratory syncytial virus (RSV), targeting the RSV-F protein with IC50 values of 1.4 nM and 1.0 nM for RSV A and RSV B, respectively. It effectively inhibits RSV infection and has demonstrated the ability to reduce viral titers in the lungs of murine models. This compound is valuable for research applications focused on developing therapeutic strategies against RSV infections. -
RSV Inhibitor
Zelicapavir is an orally active inhibitor of respiratory syncytial virus (RSV) specifically targeting the viral replication process. With an effective concentration (EC50) of less than 0.4 μM, it demonstrates potent antiviral activity. This compound is applicable in research focused on understanding RSV pathogenesis and developing therapeutic strategies against RSV infections. -
RSV Inhibitor
4-Methoxycinnamaldehyde is an RSV inhibitor known for its cytoprotective activity against respiratory syncytial virus. This compound demonstrates significant efficacy in human larynx carcinoma cell lines, effectively inhibiting RSV-induced cytopathic effects with an estimated IC50 value of 0.055 μg/mL. Its properties make it a valuable tool for research into antiviral therapies and understanding RSV pathogenesis. -
RSV Inhibitor
BMS-433771 is a potent orally active inhibitor targeting respiratory syncytial virus (RSV). It demonstrates efficacy against both RSV A and B strains, with an average EC50 value of 20 nM. This compound is a valuable tool for research on respiratory tract diseases, aiding in the understanding of RSV pathology and potential therapeutic interventions. -
RSV Inhibitor
VP-14637 is a novel respiratory syncytial virus (RSV) fusion inhibitor that demonstrates potent antiviral activity with an IC50 of 1.42 ng/mL. This compound specifically targets the fusion process of RSV, making it a valuable tool for studying viral entry mechanisms and evaluating potential therapeutic strategies against RSV infections. Its high efficacy positions VP-14637 as an important reagent for researchers working on respiratory viral diseases. -
RSV Inhibitor
RSV L-protein-IN-1 is a potent inhibitor of Respiratory Syncytial Virus (RSV) that targets viral polymerase with an IC50 of 0.089 μM. It effectively disrupts RSV mRNA synthesis by inhibiting the guanylation of viral transcripts, demonstrating an EC50 of 0.021 μM. In addition to its antiviral activity, RSV L-protein-IN-1 shows moderate cytotoxicity (CC50=8.4 μM in HEp-2 cells) and has been shown to lower virus titers in mouse models of RSV infection, making it suitable for research applications aimed at understanding RSV pathogenesis and developing therapeutic strategies. -
RSV Inhibitor
JNJ 2408068 is a potent inhibitor of respiratory syncytial virus (RSV). This compound effectively suppresses the replication of RSV A and B subtypes in pulmonary tissue, demonstrating significant antiviral activity without observable toxicity in vivo. Its minimum protective dose is approximately 0.39 mg/kg, making it a valuable tool for research into RSV pathogenesis and therapeutic interventions. -
RSV Inhibitor
3,4-Di-O-caffeoyl quinic acid methyl ester is a dicaffeoyl derivative that acts as an inhibitor of respiratory syncytial virus (RSV). It demonstrates significant antiviral activity against RSV, with an IC50 value of 0.78 μg/mL. This compound is useful for research applications focused on RSV-related infections and exploring potential therapeutic options. -
RSV Inhibitor
RFI-641 is a selective inhibitor of the respiratory syncytial virus (RSV), exhibiting an IC50 of 50 nM. This compound disrupts the binding and fusion processes of the virus by targeting the viral fusion protein. RFI-641 serves as a valuable tool in RSV research, aiding studies on viral replication mechanisms and the development of therapeutic strategies against RSV infections. -
hRSV Inhibitor
hRSV-IN-1 is a potent inhibitor of the human respiratory syncytial virus (hRSV), acting primarily by interfering with viral replication. This compound exhibits significant antiviral activity, making it an important tool for research in hRSV pathogenesis and treatment strategies. hRSV-IN-1 is particularly valuable for studies focusing on respiratory viral infections and the development of therapeutic interventions. -
RSV Polymerase inhibitor
RSV L-protein-IN-3 is an inhibitor of respiratory syncytial virus (RSV) polymerase, displaying an IC50 value of 10.4 μM and an EC50 value of 2.1 μM against RSV. It demonstrates reduced cytotoxicity compared to the clinical agent Ribavirin, making it a suitable candidate for further research into treating RSV infections. This compound is valuable for studies focusing on antiviral mechanisms and drug development targeting RSV. -
RSV Inhibitor
RSV L-protein-IN-5 is a potent inhibitor of Respiratory syncytial virus (RSV), demonstrating an EC50 of 0.1 μM. This compound primarily targets the RSV polymerase, with an IC50 of 0.66 μM, effectively blocking mRNA synthesis by inhibiting the guanylation of viral transcripts. Despite exhibiting moderate cytotoxicity (CC50 of 10.7 μM in HEp-2 cells), RSV L-protein-IN-5 shows significant antiviral activity in preclinical mouse models of RSV infection, making it a valuable tool for RSV research and therapeutic development. -
RSV Inhibitor
RSV-IN-5 is a potent dual inhibitor targeting respiratory syncytial virus (RSV) fusion proteins, effective against both wild-type and mutant strains. This compound demonstrates significant anti-RSV activity, with an EC50 of 2.0 nM against the wild-type A2 F protein and 8.1 nM against the D486N-mutant F protein. Its efficacy makes RSV-IN-5 a valuable tool in research focused on RSV-related therapeutics and understanding viral resistance mechanisms. -
RSV Inhibitor
Genkwanol C is a biflavonoid that serves as an inhibitor of respiratory syncytial virus (RSV). It demonstrates potent antiviral activity against RSV in vitro, making it a valuable tool for research on viral infections and potential therapeutic applications. Its mechanism of action offers insights into the interaction between flavonoids and viral pathogens. -
RSV Inhibitor
ent-11β-Hydroxyatis-16-ene-3,14-dione is a diterpenoid derived from the fresh roots of Euphorbia jolkinii, primarily targeting respiratory syncytial virus (RSV). This compound exhibits significant anti-RSV activity, making it a valuable tool for research in viral pathogenesis and therapeutic development focused on respiratory viral infections. Its role in inhibiting RSV positions it as a potential candidate for further exploration in antiviral research. -
RSV Polymerase Inhibitor
RSV L-protein-IN-4 is a noncompetitive inhibitor of the respiratory syncytial virus (RSV) polymerase, exhibiting an IC50 value of 0.88 μM. This compound demonstrates significant antiviral activity against various RSV strains, with an EC50 of 0.25 μM. RSV L-protein-IN-4 is essential for research into antiviral therapies targeting RSV infections. -
RSV Inhibitor
TP0591816 is a highly potent dual inhibitor targeting both wild-type and mutant respiratory syncytial virus (RSV) fusion proteins, exhibiting effective inhibition with EC50 values of 0.27 nM for wild-type and 0.70 nM for the D486N mutant. This compound demonstrates significant antiviral activity, making it a valuable tool for RSV research and potential therapeutic development. Researchers can utilize TP0591816 to explore mechanisms of RSV pathogenesis and evaluate antiviral strategies against this respiratory virus. -
RSV Inhibitor
BMS-433771 dihydrochloride hydrate is a selective inhibitor of respiratory syncytial virus (RSV), effectively targeting both RSV A and B strains. With an average EC50 of 20 nM, it demonstrates significant antiviral activity. This compound is valuable for research applications focused on respiratory tract diseases and the mechanisms underlying RSV infection and pathogenesis. -
RSV Polymerase Inhibitor
RSV L-protein-IN-2 is a noncompetitive inhibitor of the Respiratory Syncytial Virus (RSV) polymerase, exhibiting an IC50 value of 4.5 μM. This compound demonstrates significant antiviral activity against long strains of RSV, with an EC50 of 1.3 μM. It is applicable in research focused on developing therapeutic strategies against RSV infections and understanding viral replication mechanisms. -
RSV Inhibitor
BTA-9881 is a potent respiratory syncytial virus (RSV) inhibitor, demonstrating EC50 values of 48 nM, 59 nM, and 160 nM against RSV A2, RSV Long, and RSV B1, respectively. Its favorable pharmacokinetic properties make it a valuable reagent for studying RSV infection and evaluating potential antiviral therapies. BTA-9881 serves as an important tool in respiratory virus research, aiding in the development of effective treatments for RSV-related diseases. -
RSV Inhibitor
JNJ-7184 is a non-nucleoside inhibitor targeting the RSV-Large (L) polymerase. This compound exhibits potent antiviral activity, demonstrating a pEC50 of 7.86 and a pCC50 of 4.29 in HeLa cells. JNJ-7184 effectively prevents respiratory syncytial virus (RSV) replication and transcription by disrupting the initiation and early elongation stages of the viral life cycle, making it a valuable tool for research into RSV pathogenesis and potential therapeutic strategies. -
RSV Inhibitor
AZ-27 is a selective inhibitor of respiratory syncytial virus (RSV) by targeting its polymerase activity. This compound exhibits the ability to differentially suppress various RSV polymerase functions at the promoter level, effectively inhibiting the early stages of mRNA transcription and genome replication. AZ-27 is suitable for research applications focused on understanding RSV pathogenesis and developing antiviral strategies. -
RSV L protein Inhibitor
AZD4316 is an inhibitor of the respiratory syncytial virus (RSV) L protein, demonstrating significant antiviral activity against RSV A subtypes, including strain A2. This compound effectively hinders viral replication during the early stages of infection, particularly at the viral entry phase. However, its efficacy diminishes when administered 12-24 hours post-infection. AZD4316 is valuable for research focused on RSV infection mechanisms and potential therapeutic strategies. -
RSV Inhibitor
RSV-IN-13 is a selective inhibitor of respiratory syncytial virus (RSV) fusion protein, exhibiting antiviral activity. It demonstrates an EC50 of 444.2 nM against the RSV A2 strain, with a CC90 of 23.7 μM in HepG2 cells. By effectively blocking the entry of the virus into host cells, RSV-IN-13 serves as a valuable tool for research on RSV infection and pathogenesis.
